Read the Journal of Managed Care + Specialty Pharmacy (JMCP) February 2025 Issue

The Academy of Managed Care Pharmacy (AMCP) thanks the Food and Drug Administration (FDA) for the opportunity to provide comments in response to the “Expedited Program for Serious Conditions — Accelerated Approval of Drugs and Biologics” (Draft Guidance), issued on December 5, 2024.

The Academy of Managed Care Pharmacy (AMCP) issued the following statement from AMCP CEO Susan A. Cantrell, MHL, RPh, CAE, regarding President Trump’s new and proposed tariffs on U.S. imports from Canada, Mexico, and China: “Although President Trump’s new and proposed tariffs aim to level the playing field between American industries and our foreign competitors, we are concerned about the unintended, adverse consequences they may have on the cost of medicines in the U.S.

AMCP and its members advocate for bipartisan legislation that eliminates bureaucratic barriers to high-quality, innovative therapies, while lowering the bill footed by patients, families, government, employers, and other healthcare payers.

Hear from AMCP CEO Susan Cantrell about bringing accuracy to the public discourse on health care.